Terns Pharmaceuticals, Inc. (TERN) NASDAQ

Currency In USD

Terns Pharmaceuticals, Inc.

Address

1065 East Hillsdale Boulevard

Foster City, CA 94404

United States of America (the)

Phone

650 525 5535

Website

https://www.ternspharma.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

February 05, 2021

Key Executives

Name	Title	Pay	Year Born
Amy L. Burroughs	Chief Executive Officer & Director	1.17M	1971
Melita Sun Jung	Chief Business Officer	508,886	1977
Andrew W. Gengos	Chief Financial Officer & Head of Corporate Development	700,845	1964
Emil T. Kuriakose	Chief Medical Officer	819,800	1981
Robin Andrulevich	Chief People Officer	0	1966
James Kanter	Senior Vice President of CMC	0	N/A
Caryn Gordon McDowell	Chief Legal Officer	0	1970
Scott Harris	Chief Development & Operations Officer	0	N/A
Debra Sieminski	Senior Vice President of Medical Affairs	0	N/A
Theresa Clouser	Vice President of Marketing	0	N/A
Yasameen Qazen	Senior Vice President of Regulatory Affairs & Quality Assurance	0	N/A
Jeffrey R. Jasper	SVP & Senior Distinguished Research Fellow	0	N/A

Description

Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.